Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.Results showed ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% meeting criteria for obesity alone, according to the Centers for Disease ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying ...